{"schema":"rootz.ai/sec-company/v1","layer":1,"cik":"0001517022","name":"Akebia Therapeutics, Inc.","summary":"Akebia Therapeutics is a fully integrated biopharmaceutical company focused on kidney disease. It markets two commercial products: Vafseo (vadadustat), an oral HIF-PH inhibitor approved in March 2024 for anemia due to CKD in dialysis patients, and Auryxia (ferric citrate), approved for serum phosphorus control in DD-CKD and iron deficiency anemia in NDD-CKD. Its pipeline includes praliciguat for FSGS, AKB-097 for complement-mediated rare kidney diseases, and early-stage HIF molecules AKB-9090 and AKB-10108.","people":[],"products":[{"name":"Vafseo (vadadustat)","type":"service","description":"Oral HIF-PH inhibitor approved March 2024 for anemia due to CKD in adult dialysis patients; launched in U.S. January 2025."},{"name":"Auryxia (ferric citrate)","type":"service","description":"Oral medicine approved for serum phosphorus control in DD-CKD and iron deficiency anemia in NDD-CKD adults in the U.S."},{"name":"Praliciguat","type":"platform","description":"Oral, once-daily sGC stimulator in Phase 2 trial for biopsy-confirmed focal segmental glomerulosclerosis (FSGS)."},{"name":"AKB-097 (ADX-097)","type":"platform","description":"Anti-C3d-Factor H fusion protein complement inhibitor for rare kidney diseases; Phase 2 basket study planned for 2026."},{"name":"AKB-9090","type":"platform","description":"Early-stage HIF molecule targeted initially for cardiac surgery-related acute kidney injury; Phase 1 study planned first half 2026."},{"name":"AKB-10108","type":"platform","description":"Early-stage HIF molecule in preclinical development, potentially for retinopathy of prematurity in neonates."}],"partnerships":[{"partner_name":"Cyclerion Therapeutics, Inc.","partnership_type":"licensing","description":"Exclusive global license for praliciguat, including IP rights to research, develop and commercialize the asset, signed June 2021.","start_date":null},{"partner_name":"Q32 Bio Inc. and Q32 Bio Operations Inc.","partnership_type":"acquisition","description":"Asset purchase agreement signed November 2025 to acquire AKB-097 and substantially all related assets and liabilities.","start_date":null},{"partner_name":"DaVita, Inc.","partnership_type":"strategic","description":"Commercial supply agreement for Vafseo; DaVita is one of the top U.S. dialysis organizations treating dialysis patients.","start_date":null},{"partner_name":"Fresenius KidneyCare Group LLC","partnership_type":"strategic","description":"Commercial supply agreement for Vafseo; Fresenius is one of the largest U.S. dialysis organizations.","start_date":null},{"partner_name":"U.S. Renal Care (USRC)","partnership_type":"strategic","description":"Commercial supply agreement for Vafseo; USRC added a protocol for Vafseo with observed dosing for in-center patients.","start_date":null},{"partner_name":"Dialysis Clinic, Inc. (DCI)","partnership_type":"strategic","description":"Commercial supply agreement for Vafseo as part of top five U.S. dialysis organizations covering 82% of dialysis patients.","start_date":null},{"partner_name":"Innovative Renal Care (IRC)","partnership_type":"strategic","description":"Commercial supply agreement for Vafseo; IRC added a protocol for Vafseo with observed dosing for in-center patients.","start_date":null},{"partner_name":"Teva Pharmaceuticals Ltd.","partnership_type":"strategic","description":"Teva received tentative FDA approval January 22, 2026 for an Abbreviated New Drug Application for generic Auryxia.","start_date":null}],"affiliations":[],"origin":{"leaf":"c4397dd3f66b4632c702e9df95a7f785a21eed5046ee78225c34cade0225ab1e","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"e4b8f0144841680e552edeedaeb4ff7ab07dc8d308f44a9ad722c01f02eaec5e","parent":"630f41481b6cef9f46fe812cea26a686ed0b749d796c48c731c688aa23997211","source":"0001517022-26-000020","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":500,"hourly_limit":500,"remaining":0,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}